Zenas BioPharma (ZBIO) FCF Margin (2024 - 2025)
Zenas BioPharma's (ZBIO) quarterly FCF Margin came in at 370.69% in Q1 2025, up 52.02% quarter-over-quarter from 772.56% in Q4 2024.
Zenas BioPharma (ZBIO) FCF Margin (2024 - 2025) Analysis & Trends
Zenas BioPharma's FCF Margin history runs 2 years deep, the most recent figure standing at 370.69% for Q1 2025.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 370.69% in Q1 2025; TTM through Dec 2025 was 1723.51%, a 67259.0% increase from a year earlier, with the FY2025 full-year figure at 1723.51%, up 67259.0% from the prior year.
- FCF Margin advanced to 370.69% in Q1 2025 per ZBIO's latest filing, from 772.56% in the prior quarter.
- Across five years, FCF Margin topped out at 370.69% in Q1 2025 and bottomed at 772.56% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zenas BioPharma | 1.72 Bn | 1.72 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -370.69% |
| Dec 31, 2024 | -772.56% |